Back to top
more

Denali Therapeutics (DNLI)

(Delayed Data from NSDQ)

$30.91 USD

30.91
1,997,843

-0.14 (-0.45%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $30.90 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?

Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?

Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug

DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.

Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade

The consensus price target hints at a 79.6% upside potential for Denali Therapeutics (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the second quarter of 2024 in both the United States and International segments.

Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?

Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its second-quarter earnings release, given the absence of a marketed product.

Perrigo (PRGO) to Report Q2 Earnings: Here's What to Expect

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?

Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Denali (DNLI) Outperforms Industry in 3 Months: Here's Why

Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.

Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?

Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Denali's (DNLI) Candidate Selected for FDA's START Pilot Program

Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.

Why Denali Therapeutics (DNLI) Stock Might be a Great Pick

Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up

Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.

Denali's (DNLI) Pipeline Progresses Despite Stiff Competition

Denali (DNLI) forms strategic collaborations with bigwigs like Sanofi and Biogen to advance its pipeline. However, high dependence on partners for revenues remains a concern.

Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day

Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.

Sundeep Ganoria  headshot

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024

Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.

Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect?

The consensus price target hints at a 123.4% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.